DANIEL K TURNER III

CIK 1280249 · last filed 2012-02-06

DANIEL K TURNER III is a corporate insider who has filed 25 SEC Form 4 insider transactions across 2 companies since 2007. The most recent filing shows the insider bought $82.9K of OREX on Feb 6, 2012. Across all open-market trades the lifetime net is −$3.8M, making them a net seller over the disclosed history. 6 SEC filings were submitted jointly with MONTREUX EQUITY MANAGEMENT II SBIC LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

25

Lifetime Open-Market Net

-$3.80M

Filer Profile

Reported Address

2500 SAND HILL ROAD
215
MENLO PARK, CA 94025

Related Filers

MONTREUX EQUITY MANAGEMENT II SBIC LLC — 6 joint filings, latest 2010-03-22

HOWARD D PALEFSKY — 6 joint filings, latest 2010-03-22

Equity Managment III SBIC Montreux — 4 joint filings, latest 2010-03-22

Montreux Equity Management IV, LLC — 2 joint filings, latest 2018-10-19

Montreux Equity Partners V, L.P. — 2 joint filings, latest 2015-06-24

John Savarese — 2 joint filings, latest 2007-05-02

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Orexigen Therapeutics, Inc. (OREX) Delisted	Director	37,796	—	—	-$3.80M	13	2012-02-06
Pernix Sleep, Inc. (SOMX) Delisted	Director	—	—	—	$0	2	2008-06-13

Recent Filings

25 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2012-02-06	Orexigen Therapeutics, Inc. (OREX) Delisted	Buy (P)	+57,204	$82.9K	EDGAR
2011-06-06	Orexigen Therapeutics, Inc. (OREX) Delisted	Grant (A)	—	$0	EDGAR
2011-03-30	—	Sell (S)	−130,000	-$1.06M
2011-01-27	—	Grant (A)	—	$0
2010-12-23	Orexigen Therapeutics, Inc. (OREX) Delisted	Sell (S)	−100,000	-$428.5K	EDGAR
2010-12-14	Orexigen Therapeutics, Inc. (OREX) Delisted	Sell (S)	−600,000	$0	EDGAR
2010-05-28	Orexigen Therapeutics, Inc. (OREX) Delisted	Grant (A)	—	$0	EDGAR
2010-02-04	—	Grant (A)	—	$0
2010-01-19	—	Grant (A)	—	$0
2009-12-17	Orexigen Therapeutics, Inc. (OREX) Delisted	Sell (S)	−100,000	-$755.0K	EDGAR

Showing 1–10 of 25

Page 1 of 3 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.